Iodobenzamide (IBZM or iolopride) is a pharmaceutical drug used for diagnostic purposes.

[1][2] The main purpose of a brain study with IBZM is the differentiation of Parkinson's disease from other neurodegenerative diseases such as Lewy Body dementia and multiple system atrophy.

The Iodobenzamide binds to the Dopamine D2 receptors in the person’s brain and blocks excess neurons that cause an asymmetry in the brain, leaning heavily to the left side.

People that receive doses of Iodobenzamide have their brain scanned to monitor their dopamine activity.

Male patients showed a left side heavy brain asymmetry of dopamine receptor binding in a drug-naive state.